Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine is indicated for the treatment of patients with: ? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated.

Malta - English - Medicines Authority

onkovis gmbh grube 45, 82377 penzberg , germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

onkovis gmbh grube 45, 82377 penzberg , germany - azacitidine - powder for suspension for injection - azacitidine 25 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - azacitidine - powder for suspension for injection - 25 milligram(s)/millilitre - azacitidine

Canada - English - Health Canada

dr reddy's laboratories ltd - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

eugia pharma (australia) pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - eug-azacitidine is indicated for the treatment of patients with:,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ? chronic myelomonocytic leukemia [cmmol (10%-29% marrow blasts without myeloproliferative disorder)], ? acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who),,in whom allogenic stem cell transplantation is not indicated.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - azacitidine (unii: m801h13nru) (azacitidine - unii:m801h13nru) - azacitidine 100 mg

United States - English - NLM (National Library of Medicine)

seton pharmaceuticals - azacitidine (unii: m801h13nru) (azacitidine - unii:m801h13nru) - azacitidine 100 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; sucrose - azacitidine-teva is indicated for the treatment of patients with: intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), chronic myelomonocytic leukemia [cmmol (10 percent-29 percent marrow blasts without myeloproliferative disorder)], acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), in whom allogenic stem cell transplantation is not indicated

Canada - English - Health Canada

fresenius kabi canada ltd - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents